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Alzheimer's disease (AD) is a multifactorial disease. In addition to the precipitating of two proteins beta-
amyloid peptide and neurofebrillary tangles, which are the main mechanisms involved in the pathogenesis of 
AD, other factors such as inflammatory mechanisms and changes in lysosomal enzymes play an important 
part in the pathogenesis of this disease. Increased and decreased lysosomal proteases, such as cathepsin, can 
lead to functional impairment and gradual death of neurons. The aim of this review was to investigate the 
role of cathepsins in the pathogenesis of AD. To conduct this review, relevant articles published between 
2000 and 2016, and indexed in reliable databases including PubMed, Google Scholar, Scopus and Web of 
Science were retrieved. After reviewing the articles, 30 articles that directly addressed the subject of this re-
view were included in final analysis. Cathepsins exacerbate intracellular conditions in neurons, by processing 
beta-amyloid precursor protein and converting it into amyloid beta. They also play a protective role against 
AD and fight it by catalyzing the decomposition of beta-amyloids and converting them into the cut out 
forms of the carboxyl C-terminus. In addition, the 24 kDa fragment resulting from the effect of cathepsin D 
on apolipoprotein E (ApoE) is the second binding to the receptor in the ApoE. This fragment may also be 
the cause of the pathogenicity of Apo E in AD. Identifying and explaining the mechanisms involved in the 
pathogenesis of AD can play a significant role in the prevention and treatment of this disease. Since cathep-
sins play a pivotal role in the decomposition of beta-amyloid and reduction of the risk of AD, further stud-
ies can be considered an effective approach to study AD. 
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INTRODUCTION 
Recent studies have shown that switching off and 
activating the proteolytic endosomal-lysosomal sys-
tem can contribute to the pathophysiology of certain 
inflammatory diseases (Dickinson, 2002; Leichsen-
ring et al., 2008; Conus and Simon, 2010). Enzymatic 
proteolysis is accomplished by the nucleophilic at-
tack of enzymes on carbonyl, followed by general 
acid and base hydrolysis (Garcia-Touchard et al., 
2005; Doucet and Overall, 2008).  
 
In the human genome, more than 569 proteolytic 
enzymes are found, thus comprising the second larg-
est family of enzymes in humans. Extracellular pro-
teolysis is important for many biological processes 
such as tissue alteration, wound healing, and pro-
cesses development.  
 
On the other hand, extracellular proteolysis plays 
an important role in pathophysiologic processes 
such as cancer, chronic inflammatory diseases, car-
diovascular diseases such as atherosclerosis and 
restenosis, activation of precursor proteins 
(Masoudi et al., 2015; Khayeri et al., 2016) (including 
pro-enzymes and prohormones), antigen presenta-
tions at the cell surface by major histocompatibility 
complex (MHC) II, rearrangement of bone, 
keratinocyte differentiation, hair follicle cycle, apop-
tosis, arthritis, Parkinson's disease, and AD 
(Roshangaran and Masoudi, 2016; Masoudi et al., 
2017).  
 
Generally, in diseases caused by lysosomal enzymes, 
there is an impairment of brain development, retar-
dation, or mental disorders, and the presence of 
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intracellular protein deposits is one of the character-
istics of this type of disorders, as with AD 
(Noormohammadi et al.; Masoudi et al., 2013).  
 
Studies have also shown an increase in the levels of 
cathepsins B and D in the brain lysosomal system of 
patients with AD in the early stages of the disease. 
After being synthesized in the endoplasmic network 
and passing through post-translational modifications 
via two receptors, CD-MPR and CI-MPR, cathep-
sins enter the lysosomal system, mainly the primary 
endosomal vacuoles containing the Rab-5 marker. In 
the early stages of AD, the levels of cathepsins B and 
D increase inside the primary endosomes containing 
the Rab-5 marker due to the increased CD-MPR 
receptor expression. In addition, in the brain tissues 
of AD patients, the levels of cathepsin B, and possi-
bly cathepsin D, have been observed to increase, 
representing the increased expression of these two 
enzymes genes.  
 
However, the experimental studies using the RT-
PCR technique have shown that in the peripheral 
system of patients, including peripheral blood lym-
phocytes and fibroblasts, there is a reduction in tran-
scription in cathepsin D (Nixon et al., 2005; Ur-
banelli et al., 2008). Regarding the role of cathepsins 
C and D in AD, there are controversial arguments 
and evidence whose general focus is on the involve-
ment of these two enzymes in the emergence or pre-
vention of AD.  
 
These two enzymes are capable of being involved in 
the beta-amyloid precursor protein (βAPP) pro-
cessing and amyloid beta production. Perhaps the 
reason for increase in the levels of beta amyloids in 
the lysosomal system and especially the primary en-
dosomes in the early stages of the disease, with the 
increasing activity of the lysosomal system, including 
the increase in utophagy and endocytosis, along with 
increase in the levels of lysosomal enzymes, especial-
ly cathepsins B and D, is the direct or indirect effect 
of these cathepsins in processing the βAPP to pro-
duce beta amyloid.   
 
These two cathepsins in vivo have beta- and gamma-
secretase activity compared to the βAPP models 
(Urbanelli et al., 2008; Chen et al., 2010). The pre-
vailing argument is that the breakdown of beta-
amyloids, except for certain specific pathological 
conditions, plays a major role in these proteolytic 
enzymes,  and the beta-amyloids produced through-
out the endocytosis and phagocytosis processes 
may be degraded after being transported to lyso-
somes by the proteolytic enzymes, and particularly 
the cathepsins, present in them, which indicates the 
role of cathepsins B and D in clearing amyloid 
plaques and developing AD(Mueller-Steiner et al., 
2006).  
 
Therefore, with respect to available evidence and 
significant role of cathepsins in the pathogenesis of 
AD, the aim of this review was to investigate the 
role of cathepsins in the pathogenesis of AD. 
 
To conduct this review, relevant articles published 
between 2000 and 2016, and indexed in reliable 
databases including PubMed, Google Scholar, Scopus 
and Web of Science were retrieved. The articles with-
out abstract and full text in English were excluded 
from the study. After reviewing the articles, the 
articles (n: 30) that directly addressed the role of 
cathepsins in AD were included in final analysis.  
 
RESULTS 
The lysosomal system mainly comprises a family of 
intracellular components that are permanently 
linked to each other. This system includes more 
than 80 types of acid hydrolases, including cathep-
sins. Cathepsins degrade most of the proteins enter-
ing the lysosomal system rapidly into their amino 
acid components.  
 
However, chemical and enzymatic post-
translational modifications throughout the aging 
process and certain diseases yield proteins that are 
more resistant to degradation so that they are not 
completely degradable or are partly degraded. These 
proteins accumulate as a result of this abnormality. 
Cathepsin is one of the enzymes that are released 
into the bloodstream and cellular fluids under 
stress. Cathepsins represent highly susceptible lyso-
somal proteases that play an important role in lyso-
somal apoptosis and induce metastasis in the extra-
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Role Results 
Cathepsins B and D in diabetics 
 
Transcription of lysosome-associated membrane protein 2 and cathepsins B and 
D decreased in diabetics (Masini et al., 2009). 
Cathepsins B and D in type 2 
Diabetes 
  
 
  
They observed that autophagy in beta cells was activated after induction of stress 
as a protective mechanism. However, the increase in observed autophagosomes 
in diabetic patients and in beta cells under treatment with free fatty acids can 
reflect a decrease in autophagic flux due to decreased lysosome formation and 
cathepsin (Las and Shirihai, 2010). 
Cathepsin in the development of 
epilepsy 
  
 
  
  
The genes involved in idiopathic generalized epilepsy; this gene is located on the 
long arm of chromosome 21, and consists of three short exons and two introns. 
The coded protein by the cystatin B (CSTB) gene is distributed among most cells 
and tissues of the body and the cysteine inhibitor is the proteases of the cathep-
sin B or 3 family; if the mutation of this gene and the increase in cathepsin B 
occur, this type of epilepsy occurs (Lalioti et al., 2003). 
Cathepsin in the development of 
epilepsy 
 
  
The unstable expansion of minisatellite in the promoter region of the CSTB gene 
is the most common mutation in patients with equine protozoal myeloencephali-
tis and leads to a decrease in the level of mRNA and an increase  in cathepsin B, 
and thus development of epilepsy (Alakurtti et al., 2005). 
Cathepsin in the development of 
epilepsy 
 
Point mutation c.212A>C in the exon 3 of the cystatin B gene, which leads to 
the replacement of glutamine with proline and reduction in the binding of cyto-
sine B to cathepsin B, and thus epilepsy (De Haan et al., 2004). 
Cathepsin in the development of 
keratoconus 
 
 
  
  
  
The total protein in the cornea is reduced. Theoretically, a small increase in the 
quantities of degenerative enzymes and a reduction in the quantities of proteinase 
inhibitors can lead to degeneration of the stroma extracellular matrix. Levels of 
degenerative lysosomal enzymes, such as esterase and acid phosphatase, and 
those of the matrix metalloproteinases in the cornea, such as cathepsins G and B, 
increase in patients with keratoconus (Sawaguchi et al., 1989; Zhou et al., 1998; 
Määttä et al., 2006). 
Table 1: Cathepsin as a biomarker in a variety of diseases 
cellular matrix. 
 
Cathepsin is a biomarker for many diseases including 
cancer, diabetes, keratoconus, and epilepsy. Table 1 
shows the relationship between catepsin and its role 
in the pathogenesis of various diseases (Lalioti et al., 
2003; Alakurtti et al., 2005; Määttä et al., 2006; Masini 
et al., 2009; Las and Shirihai, 2010).  
 
Generally, doctors may use a certain number of 
common laboratory tests, such as vitamin B12, T4, 
thyroid-stimulating hormone, complete blood cell 
count, electrolyte test, the erythrocyte sedimentation 
rate, HIV antibody, the rapid plasma reagin, drug 
screen, as well as computed tomography (CT), mag-
netic resonance imaging (MRI), (Tau/Aß42), Apo E, 
PS1, PS2, and amyloid precursor protein (APP) gen-
otype to diagnose and differentiate AD from other 
causes of amnesia (Table 2).  
The cathepsins are divided into three groups based 
on the amino acids of their active sites: a) cysteine 
cathepsins (B, S, K, V, F, L), b) aspartate cathepsins 
(E, D), and c) serine cathepsins (G)(Garnero et al., 
1998; Sambrano et al., 2000). Cathepsins are active 
in acid pH and are produced and synthesized in the 
form of zymogen called procathepsin, where the 
propeptide of the N-terminal is isolated either as 
enzymatic or via the autocatalytic separation of pro-
peptides, and activated under acidic conditions and 
is converted to mature cathepsin through the auto-
proteolytic pathway (Turkington, 1992; Yang et al., 
2013).  
 
In total, the substrates and the necessary materials 
enter the lysosomal system via two pathways: 1. 
Heterophagy including receptor-mediated endocy-
tosis, pinocytosis and phagocytosis for transporting 
extracellular materials into lysosomes; 2. autophagy 
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Table 2: The tests used for differential diagnosis of Alzheimer's disease from other forgetfulness 
causing diseases (Nixon, 2007) 
for transporting intracellular materials into lyso-
somes. Both of these pathways are associated with 
the processing of βAPP and the pathogenesis of 
AD. Amyloid beta is typically produced in the au-
tophagic and endocytotic processes (Nixon et al., 
2005; Urbanelli et al., 2008; Kokjohn and Roher, 
2009; Lee et al., 2010) (Figure 1).  
 
In autophagic pathway, βAPP-containing organelles 
and in the endocytic system, extracellular materials 
along with the cytoplasmic membrane of endosomes 
are the major sources of βAPP. In this case, the beta
-amyloid produced by lysosomes is efficiently de-
graded. If the endocytotic process is reduced or ac-
celerated, the amount of produced amyloid beta 
proportionately increases or decreases as well 
(Bhojak et al., 2001).  
 
Dynamic and active changes in the contents of the 
substrates, the hydrolyses and the internal pH, be-
tween autophagosomes and endosomes, provides 
suitable conditions, depending on the cell health, 
for both the production and the breakdown of beta
-amyloid, and therefore in both of these pathways 
(autophagy and endocytosis), beta-amyloid is nor-
mally produced. But, notably the beta-amyloid pro-
duced in this pathway are mainly degraded, after 
being transported to lysosomes, by cathepsins, 
which have the adequate specificity of decomposi-
tion for amyloid beta.  
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Test type Test Sample Usage Application 
Imaging 
techniques 
 
 
Computed 
tomography 
(CT) 
 
Full-body 
scan 
 
 
Differentiation of Alzheimer's 
disease from other disorders, 
diagnosis of Alzheimer's dis-
ease in advanced stages 
Stroke and cerebral atrophy (Brain 
degeneration in the final stages of 
Alzheimer's disease) 
 
Imaging 
techniques 
 
 
Magnetic 
resonance 
imaging 
(MRI) 
Full-body 
scan 
 
 
Differentiation of Alzheimer's 
disease from other disorders, 
diagnosis of Alzheimer's dis-
ease in advanced stages 
Stroke and cerebral atrophy (Brain 
degeneration in the final stages of 
Alzheimer's disease) 
 
Less com-
mon labora-
tory tests 
 
 
 
 
Association 
between 
amyloid beta 
and Tau 
protein 
(Tau/Aß42) 
 
Cerebrospinal 
fluid 
 
 
 
 
 
Helping differentiate Alzhei-
mer's against other types of 
amnesia 
 
 
 
 
In patients with symptoms, de-
creased levels of amyloid beta 42, 
accompanied by an increase in Tau 
protein levels, indicates an in-
creased risk of developing Alzhei-
mer's disease, regardless of the 
cause of the disease. 
Less com-
mon labora-
tory tests 
 
 
 
G e n o t y p e 
Apo E 
 
 
 
 
Blood 
 
 
 
 
 
Genotyping ApoE genotype 
and conducting complementary 
tests to confirm  Alzheimer's 
disease diagnosis or rule out the 
likelihood of its development 
 
Apolipoprotein E (ApoE)/e4 in-
creases the risk of Alzheimer's 
disease at an early age in sympto-
matic patients. The variations of 
the e2 and e4 alleles are also asso-
ciated with dyslipidemia. 
Less com-
mon labora-
tory tests 
PS1 
 
 
Blood 
 
 
Genetic mutation test (There 
are only a few laboratories) 
 
Considered the cause of the early 
onset of familial Alzheimer's dis-
ease in about half of the cases. 
Less com-
mon labora-
tory tests 
PS2 
 
 
Blood 
 
 
Genetic mutation test (There 
are only a few laboratories) 
 
Familial Alzheimer's disease, a 
mutation observed in a limited 
number of families 
Less com-
mon labora-
tory tests 
APP 
 
 
Blood 
 
 
The genetic mutation test is still 
being studied and is not clini-
cally available. 
Familial Alzheimer's disease, a 
mutation observed in a limited 
number of families 
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Figure 1: A schematic representation of the lysosomal system in the brain that represents the path-
ways of beta-amyloid precursor protein processing in endosomes and autophagosomes 
(Riemenschneider et al., 2006). PAS: Pre-Autophagic Structure; AP: Autophagosome; 
AL: Autophagolysosome; LE/MVB: Late Endosome/Multivesicular Body; EE: Early Endosomes; 
SE: Secondary Endosomes; LE: Late Endosomes. 
Figure 2: Co-accumulation of cathepsin B and amyloid beta in amyloid plaques in brain tisdues of 
transgenic mice aged 16-20 months with human beta-amyloid precursor protein (Mueller-Steiner et 
al., 2006), (A): Immunostaining against cathepsin B with Cat B antibody makes the tissue section 
red; (B): Immunostaining against beta-amyloid by anti-amyloid veta antibody 3D6 makes the tis-
sue green; (C): The yellow signal in the integrated A and B Figure illustrates the presence of both 
amyloid beta and cathepsin B inside the plaque (Mueller-Steiner et al., 2006). 
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Generally, beta amyloid levels are determined by the 
balance between production and degradation, and 
any defect in the proteolytic degradation of this pep-
tide can contribute to the pathogenicity and patho-
genesis of AD (Perry et al., 1987; Zhou et al., 2006; 
Chen et al., 2010). Two Alzheimer's disease-
associated pathways-heterophagy and autophagy-are 
illustrated in Figure 2 (Nixon, 2007). 
 
DISCUSSION 
Some achievements suggest that the gene expression 
and production of cathepsin D multiply in AD, 
which is due to neurolysis and increased concentra-
tion of this protease in the cerebrospinal fluid 
(Mueller-Steiner et al., 2006; Riemenschneider et al., 
2006; Majumdar et al., 2007; Lee et al., 2010; Sundelöf 
et al., 2010). Chen et al., (2010) showed that an in-
crease in blood cholesterol levels in humans is a pre-
disposing factor for AD. They argued that increased 
cholesterol levels in the endosomal system affected 
the structure and function of lysosomes.  
 
In these experiments, it has been shown that the spe-
cific activity of cathepsin D and the acid phosphatase 
in the lysosomal system decreases due to an increase 
in cholesterol levels. Changes in cholesterol hemosta-
sis can increase the production of beta amyloid in the 
brain, but it does not specify the mechanism and the 
extent to which circulating cholesterol can affect beta
-amyloid levels as well as the spreading of pathology 
in AD. One mechanism for entering cholesterol into 
receptor-dependent endothetic neurons. As the level 
of cholesterol in the circulation increases with the 
change in the integrity and the hemostasis of the 
brain-blood barrier, the amount of cholesterol enter-
ing the brain tissue increases as well. As a result of 
this increase, cholesterol-dependent cholesterol-
derived endostiosis increases in neurons.  
 
Along with the endocytotic process, some of the 
cytoplasmic membrane of the neurons also enters 
the cells as endosomal vacuoles, which themselves 
contain some βAPP, resulting in a higher amount of 
βAPP substrate entering into the endosomal-
lysosomal system. This endosomal-lysosomal system 
thus turns into a place where there is necessary secre-
tases for converting βAPP to beta-amyloid, and 
therefore the production of amyloid beta will in-
crease.  
 
In addition, the increase in cholesterol levels in the 
endosomal system affects the structure and func-
tion of lysosomes, which reduces the specific activi-
ty of cathepsins D, B, and E and acid phosphatase 
(ACP) in the lysosomal system. This matter may 
also be the reason for the mechanism of AD in 
sporadic cases of this disease due to increased cho-
lesterol (Chen et al., 2010). 
 
Other studies have shown that cathepsin D can 
contribute to the pathogenesis of AD by degrading 
ApoE. Although the exact mechanism of the role 
of ApoE in AD is unknown, new findings have led 
to the suggestion that the remaining residues from 
proteolytic degradation of ApoE may be involved 
in the pathogenesis of this disease. Aspartic prote-
ases in the lysosomal system of the brain cells seem 
to be involved in ApoE proteolytic activity. Cathep-
sins D and E are two types of these aspartic prote-
ases. ApoE proteolytic activity is related to either of 
these two cathepsins. The involvement of these two 
cathepsins has been demonstrated in the proteolysis 
of the ApoE derived from human purified cathep-
sins D and E with two types of ApoE, consisting of 
lipid-free neo-compound ApoE3 and ApoE4 as 
well as human ApoE4 lipoped with dipalmitoyl 
phosphatidyl cholin (DPPC) (Zhou et al., 1998). 
 
Cathepsin D on both ApoE3 and ApoE4 lacked 
lipid and the ApoE4 with lipid exhibited the same 
degradation effect. The dominant product in this 
process is a 24 kDa fragment that is similar to that 
obtained from the brain tissues of AD patients. 
However, cathepsin E only exerts effect on ApoE3, 
which is free of lipid, and does not affect lipid-
containing ApoE4. This is despite the fact that the 
proteolysis-derived pattern of cathepsin E on the 
lipid-free ApoE4 and the ApoE3 is different from 
the pattern of its degradation by cathepsin D that is 
similar to the tissue pattern of patients. Regarding 
these results, it seems that cathepsin E is more like-
ly to contribute to the degradation leaing to the 
ApoE pathogenesis in the brain of AD patients, 
compared with cathepsin D.  
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On the other hand, histological studies performed 
on the sections of AD patients suggest the simulta-
neous accumulation of cathepsin D and ApoE in a 
series of senile plaques and Tangles. There is also a 
positive correlation between the duration of the dis-
ease and the percentage of these plaques. Additional 
results have suggested that the 24 kDa fragment re-
sulting from the effect of cathepsin D on ApoE is 
the second binding to the receptor in Apo E. The 
cause of the pathogenicity of ApoE in AD may also 
be the same (Zhou et al., 2006).  
 
In addition to the above evidence, it has been shown 
that the levels of the proteolytic lysosomal enzymes 
present in the microglia are higher than those in the 
macrophages of the J774 macrophages. Microglia are 
capable of scavenging beta-amyloids by means of 
scavenger receptor type A (SRA), but due to their 
near-neutral pH (about 6) inside their lysosomes, 
these lysosomal enzymes, in particular, cathepsins, 
fail to provide enough activity to break down beta-
amyloids in microglia. In the pathologic sections of 
the brain tissues of AD patients, the beta-amyloid-
containing microglia are frequently found around 
amyloid plaques. It seems that if the pH in the lyso-
somes of the microglia resches more favorable lev-
els, the beta-amyloid proteolytic decomposition will 
be accomplished more optimally.  
 
In experimental models, the use of inflammatory 
agents, such as interleukin 6 and macrophage colony 
stimulating factor, allowed microglia to decompose 
beta-amyloid. It can also be said that the mutation in 
the PS1 gene causes lysosomal disorders, and in the 
event of mutations or the mutations leading to de-
creased activity or deletion of the PS1 gene, certain 
impairments of the lysosomal system occur, includ-
ing structural disorders such as enlargement and ac-
cumulation of lysosomal mediators, impaired acidity 
of the endosomes and autophagosomes, as well as 
the decreased activation of cathepsin D, as the main 
lysosomal aspartic protease.  
 
Although the pathological effect of these mutations 
in AD has been frequently reported to be the pro-
duction of amyloid beta from its precursor, βAPP, 
but in this regard, it is important to note that this 
effect is not observed in all diseases that occur due 
to a mutation in PS1, so in this case, with respect to 
AD, in addition to increasing amyloid beta produc-
tion, loss of another function or the other specific 
and biological functions of the PS1 can be one of 
the most important causes of the onset of the dis-
ease. Experimentally, the elimination of the PS1 
gene results in complete loss of autophagy, while 
this effect has the least possible effect on lysosome-
independent proteolytic systems.  
 
Studies have determined that the role of PS1 in the 
process of lysosomal proteolysis is to assist the 
acidification process of the internal contents of the 
components of the lysosomal system. Naturally, for 
the internal contents of the endolysosomes and 
autophagolysosomes to be acidic, the system re-
quires an energy-dependent proton pump called 
vacuolar [H +] ATPase (V ATPase). The acidifica-
tion of the internal contents of these lysosomal 
structures is an important process in their matura-
tion, as well as in the activation of proteolytic en-
zymes such as cathepsins L, D, and B. This proton 
pump consists of a membrane complex called V0 
and a cytosolic complex called V1, each of which in 
turn consists of several subunits.  
 
After synthesizing the subunits in the endoplasmic 
network and completing the post-translational pro-
cesses on them, the subunits are transported to the 
endosomes and autophagosomes and are placed in 
their cell membrane, thereby performing the task of 
acidifying the endolysosomes and the autophagoly-
sosomes. Studies have shown the role of PS1 in 
completing the post-translational modification on 
the V0a1 subunit of this pump for n-glycosylating it 
in the endoplasmic network.  
 
The V0a1 subunit, after completing the translation 
process in the endoplasmic network, quickly con-
tacts with an enzyme in the endoplasmic membrane 
called the oligosaccharyltransferase (OST) via phys-
ical interaction with the PS1. By doing so, a part of 
the V0a1 protein structure is in appropriate contact 
with the active site of the OST. It has been shown 
that in the case of mutation or deletion of the PS1 
gene, this process is impaired or not performed and 
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thus V0a1 cannot be placed in the membrane of ly-
sosomal structures. The absence of this subunit in 
the membrane of lysosomal structures, in turn, leads 
to the formation of the V-ATPase complex, and as a 
result of the acidification of the inner contents of 
lysosomal vacuoles, their maturity is confused.  
 
If the process of acidification of these structures is 
not carried out, cathepsin will not be activated for 
several reasons. For example, the acidification of 
lysosomal structures is necessary for separation of 
CI-MPR from cathepsins. If the lysosomes are not 
acidic, these receptors will still remain bound to the 
cathepsins and will not allow them to be activated.  
 
On the other hand, the environment should be acid-
ic for the full maturity of proteolytic cathepsins. 
Apart from these cases, as repeatedly mentioned in 
this article, for the maximum function of cathepsins, 
there is a need for an acidic environment. Whether it 
is possible to examine the changes in the pattern of 
cathepsins for the diagnosis and assessment of dif-
ferent stages of AD is still unclear and many studies 
have been carried out in this regard. 
 
CONCLUSION  
In general, it can be concluded that beta-amyloid 
degradation, except for certain specific pathological 
conditions, represents the major role of cathepsin, 
and the beta-amyloid produced throughout the en-
docytosis and phagocytosis are degraded by cathep-
sin after being transported to the lysosomes. The 
specific activity of cathepsin D and the acid phos-
phatase in the lysosomal system decreases due to 
increased cholesterol levels. This may also be the 
reason for the mechanism of AD in the sporadic 
cases of this diseases due to high blood cholesterol 
levels. In addition, the 24 KD fragment resulting 
from the effect of cathepsin D on ApoE contains a 
second binding to the Apo E receptor. This frag-
ment may be the reason for the pathogenicity of 
Apo E in AD. 
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